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ABSTRACT 
 
 
MicroRNAs (miRNAs) are small, non-coding regulatory RNAs that regulate gene 
expression. miRNAs exert inhibitory effects on gene expression via 
complementary binding to cognate messenger RNA (mRNA) transcripts, and 
subsequent degradation of the targeted transcripts. miRNAs are abundant and 
have many thousands of potential gene targets – only a few of which are true 
targets. This project involves testing a potential enhancement in the prediction of 
miRNA target sites via cap analysis gene expression (CAGE) tags, possibly 
conferring increased specificity in miRNA predictions. To test this potential 
prediction tool, unique CAGE predicted miRNA target sites are identified and 1 cell 
stage Danio rerio embryos are injected with RNA constructs containing the 
predicted miRNA target site linked to a fluorescent probe. Both ‘wild type’ and 
‘mutant’ target sites are injected, and expression patterns of the target gene 
observed to confirm the existence of a ‘true’ predicted miRNA target site. Two 
CAGE predicted target sites were tested (cxcr7b and nploc4) and both validated 
as true target sites, indicated by differential gene expression patterns seen 
between WT and mutant target sites (significantly reduced expression is seen in 
WT embryos due to miRNA mediated degradation). These results show a potential 
for future use of CAGE tags in miRNA prediction. 
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INTRODUCTION 
 
 
 
1.1 MicroRNAs 
 
 
MicroRNAs (miRNAs) are small (~22nt), non-coding, regulatory RNAs expressed 
in multicellular organisms that play a functional role in the regulation of gene 
expression. miRNAs were first discovered during the characterization of C. 
elegans genes controlling larval development, wherein lin-4 and let-7 RNAs were 
found to exhibit temporal expression during C. elegans development (Reinhart et 
al., 2000, Lee et al., 2003). 
 These miRNAs can modulate a multitude of different processes including (but not 
limited to) developmental timing, haematopoiesis, organogenesis, apoptosis and 
cell proliferation (Zhao and Srivastava, 2007), through binding to partially 
complementary sites within 3’ untranslated regions (UTRs) of mRNAs in animals 
and exerting inhibitory effects on gene translation (Bartel, 2004). miRNAs are 
estimated to regulate up to two-thirds of the mammalian transcriptome and, as 
such, miRNA perturbations are thought to be closely linked to many diseases, and 
may show promise as clinical targets for disease treatment (Chang and Mendell, 
2007, Soifer et al., 2007, Sassen et al., 2008, Lu et al., 2008). 
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1.2 MicroRNA biogenesis 
 
Animal miRNA biogenesis involves, first, transcription of miRNA genes via RNA 
polymerase II (Pol II) within the nucleus – generating a several kilobase long, 5’ 
capped and 3’ polyadenylated primary miRNA transcript (pri-miRNA) containing 
multiple ~80nt stem loops. Pri-miRNAs are then cropped by a microprocessor 
(Drosha-DCGR8) complex (Han et al., 2004) to produce a ~70nt pre-miRNA. This 
pre-miRNA contains a ~2nt overhang that is detected by nuclear export factor 
exportin 5 (EXP5), which mediates exportation of the pre-miRNA from the nucleus 
to the cytoplasm (Figure 1). Once exported, cytoplasmic RNase III Dicer catalyses 
a second processing step in which the pre-miRNA is cleaved ~22nts from the 
terminal loop of the double stranded RNA to produce a ~22nt miRNA duplex (Park 
et al., 2011). This duplex is then loaded into an argonaute containing miRNA 
induced silencing complex (miRISC), wherein one strand of the duplex remains as 
a mature miRNA and the other (passenger) strand is degraded (based on the 
thermodynamic stability of the 5’ ends of each duplex strand (Khvorova et al., 
2003)).  
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Figure 1: Illustration of the miRNA processing pathway, showing gene transcription 
via RNA Polymerase II producing a capped and adenylated Pri-miRNA. Further 
processing by the Drosha-DGCR8 microprocessor complex produces a stem-loop 
containing pre-miRNA which is transported from the nucleus to the cytoplasm via 
Exportin-5. Dicer then splices the pre-miRNA, producing a miRNA duplex, one strand 
of which is degraded, while the other is incorporated into the RISC as a mature 
miRNA. Source: Kim (2005) MicroRNA biogenesis: coordinated cropping and dicing. 
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1.3 The RNA induced silencing complex 
 
The miRISC comprises a ~22nt miRNA strand, the endoribonuclease Dicer, the 
double stranded RNA binding protein TRBP and the argonaute protein Ago2 
(Gregory et al., 2005, Rand et al., 2004). It is the miRISC that exerts inhibitory 
effects on gene expression. RNA interference (RNAi) induced by the RISC can be 
defined as small interfering RNA (in this case, miRNA) guided, site-specific 
cleavage of an mRNA target. The miRNA itself is responsible for the specificity of 
the cleavage, acting as a guide that leads the RISC to its target through 
complementary Watson-Crick base pairing with cognate mRNA transcripts. 
Argonaute 2 acts by binding to the transcript and orientating the transcript into a 
position facilitating target recognition for cleavage or silencing through recruitment 
of gene-silencing proteins as seen in figure 2 (Pratt and MacRae, 2009). The 
result of miRISC action is that of post-transcriptional repression of the mRNA 
target, which may be achieved through multiple proposed mechanisms including: 
Co-translational protein degradation; inhibition of translation elongation; premature 
termination of translation; and inhibition of translation initiation (Eulalio et al., 
2008). While the exact mechanisms of miRISC action are under debate, the end-
result is that of repressing translation of the target mRNA, promoting degradation 
of the target mRNA, or both (Guo et al., 2010). 
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1.4 miRNA specificity 
 
Selective miRNA targeting is an important characteristic of the miRISC, with 
specific conditions governing the selection of targets for translational repression.  
Base complementarity between nucleotides 2-8 of the 5’ region of miRNA (the 
‘seed’ region) and the target mRNA has particular importance in targeting (Jinek 
and Doudna, 2009). This seed region most commonly binds to target sites within 
the 3’ untranslated region (3’ UTR) of mRNAs and complementarity to this region, 
even by itself, is a strong indicator of potential miRNA targeting. In addition to 
seed region complementarity, complementarity to the 3’ region of the miRNA may 
also contribute to effective binding of a target mRNA (Shkumatava et al., 2009). 
Figure 2: Illustration of RNA induced silencing complex action, from miRNA 
incorporation, mRNA targeting and Argonaute 2 mediated cleavage. Source: 
http://www.biologie.uni-regensburg.de/Biochemie1/Research/index_1.htm 
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Further to this, both the miRNA seed region and the complementary 3’ UTR target 
site show evolutionary conservation (Friedman et al., 2009, Gaidatzis et al., 2007). 
In addition, it has been shown that target site accessibility plays a role in miRNA 
target site recognition (Kertesz et al., 2007), with diminished target accessibility 
linked to reduced translational repression. The aforementioned factors affecting 
miRNA targeting can be used to make predictions concerning potential miRNA 
target sites – and, indeed, multiple tools exist that use existing gene sequence 
databases to predict potential target sites for specific miRNAs, through the use of 
an algorithm incorporating parameters linked to seed region complementarity and 
evolutionary conservation of the target site.  
 
1.5 miRNA target prediction 
 
Predicting miRNA target sites can be a useful tool, with legitimate target site 
predictions allowing elucidation of miRNA functions at a system wide level, and 
exploration of the potential for miRNA as therapeutic targets. While exploration of 
miRNA target sites could be useful for the determination of miRNA functions and 
contributions to healthy or diseased states, current target site prediction methods 
are far from flawless. Such miRNA target site prediction tools include TargetScan 
(Lewis et al., 2005), PicTar (Grun et al., 2005) and  RNAhybrid (Rehmsmeier et 
al., 2004) to list but a few. These prediction tools generally rely on 
thermodynamically based RNA:RNA duplex binding interactions, optimal free 
energy calculations, complementarity to the miRNA seed region and orthologous 
conservation of the mRNA target site to predict miRNA target sites within 3’ UTRs 
7 
 
(Mazière and Enright, 2007). Generally, they do not consider binding sites that 
may appear outside of the 3’UTR (or, if they do – false positive prediction rates are 
increased) – relying on a perfect or near-perfect Watson-Crick base-pairing 
between the miRNA seed region and a sequence within the 3’UTR. This does not 
account for mRNA targets that show imperfect base pairing with the 5’ miRNA 
seed region, yet appear to compensate through additional base pairing to the 3’ 
end of the miRNA  (Brennecke et al., 2005).  Further, with the potential for miRNA 
targeting through as little as base pairing between nucleotides 3-9 (inclusive) and 
allowing for mismatches in nucleotides 1 and 2 of the seed region, this results in 
6nt long sequences that have the potential to bind to the 3’UTR of mRNAs. Of 
course, not every sequence complementary to one specific 6nt miRNA region will 
be a true miRNA target and, as such, false positive predictions are substantial 
(generally considered to be ~30%)(Lewis et al., 2003). Couple this with relatively 
low-throughput miRNA target site validation techniques (the vast majority of 
predicted targets have not been experimentally validated), and you are left with a 
large pool of potential miRNA target sites which have not been experimentally 
validated and show a large number of false positive predictions. With this current 
state of affairs, improvements to current target site prediction models would be 
valuable in future work within the field of miRNAs, and much can be gained 
through the reduction of potential false positive target site predictions. 
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1.6 Cap Analysis of Gene Expression 
 
Cap analysis of gene expression (CAGE) is a high-throughput sequencing method 
that allows identification and quantification of RNA transcripts in biological 
samples (Kodzius et al., 2006, Shiraki et al., 2003) This is achieved through the 
identification and quantification of unique sequence tags (small ~27 nucleotide (nt) 
fragments from the start of mRNA transcripts) corresponding to the 5’ ends of 
mRNA present within a sample. In the CAGE method, a cap-trapper full length 
cDNA library (Carninci et al., 1996) of the total RNA extracted from a biological 
sample is prepared using oligo dT primers (Figure 3). Following cDNA synthesis, a 
biotin group is attached to the diol residue of the cap structure of any present 
cDNA. Once ‘capped’ by a biotin group, the cDNA is linked with a biotinylated 
‘linker’ at the 5’ end that contains recognition sites essential for cloning and 
endonuclease restriction. The cDNA is then cleaved with EcoP151 (class II) 
restriction enzyme to produce (27nt) 5’ tag fragments, followed by the attachment 
of a second linker at the 3’ end to allow for amplification. Subsequent selection of 
the capped cDNA fragments can be performed via streptavidin magnetic beads 
that trap the biotin residue and allow elimination of non-capped and incompletely 
synthesised cDNA. These 5’ tags can then be amplified via PCR, sequenced via 
the Sanger method (Sanger and Coulson, 1975), identified via comparison to a 
known genome and quantified. This method is comparable to other tag 
sequencing methods (SAGE (Velculescu et al., 1995) and MPSS (Reinartz et al., 
2002)), offering the advantage of being relatively high throughput and allowing 
rather precise quantification of present mRNA. 
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Figure 3. Graphical representation of the CAGE method used in mRNA identification and 
quantification. Kodzius et al. (2006) CAGE: Cap analysis of gene expression. 
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1.7 The Project 
 
It is with this in mind that I (under the guidance of the Mueller lab group) undertook 
a 15 week project with an aim to investigate a potentially improved miRNA target 
site prediction algorithm based on cap analysis of gene expression (CAGE) data 
gleaned from research into dynamic core promoter usage during development in a 
vertebrate (zebrafish) embryo (Nepal et al., 2013). Nepal et al.’s research involved 
the identification of transcription start sites (TSSs) by CAGE analysis of RNA 
samples collected throughout embryonic development, and the quantification of 
temporal TSS usage on a global scale. CAGE allows the high-throughput 
identification of sequence tags corresponding to the 5’ ends of mRNA at 
biotinylated cap sites (Affymetrix/Cold Spring Harbor Laboratory ENCODE 
Transcriptome Project, 2011, Kapranov et al., 2007, Project, 2009), and the 
identification of transcriptional start sites within RNA samples (Shiraki et al., 2003). 
Figure 4 (below) represents a workflow diagram followed by Chirag Nepal to 
identify potential miRNA target sites for experimental validation within the early 
stage zebrafish embryo through the use of CAGE.  
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Figure 4: Diagram representing the workflow of Chirag Nepal for identifying active miRNA 
targets within the zebrafish for examination as CAGE predicted ‘true’ miRNA target sites. 
Once an RNA library is prepared, CAGE tags are mapped to potential miRNA seed target 
sites within 3’ UTRs. 
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This examination was prompted after a secondary finding within the CAGE data of 
the Nepal 2013 paper showed CAGE tag enrichment within the 3’UTRs of mRNA 
sequences, potentially corresponding to mRNA cleavage sites (Table 1 & Figure 
5, below).  
 
 
  
3'UTR with CAGE tags 3' UTR without Cage Tags 
miRNA target 17497 8164 
Non miRNA Target 566 1610 
Table 1: Data from Nepal et al. 2013 shows enrichment of CAGE tags at predicted miRNA 
target sites, suggesting a potential for CAGE assisted miRNA prediction. 
 
 
 
 
 
  
 
Graphical representation of CAGE tag enrichment within 3’ UTRs and surrounding 
maternal miRNA seed sites can be seen below, in Figure 6: 
 
 
Figure 5: A Schematic representation of CAGE tag enrichment within an mRNA 3’UTR 
indicating the presence of potential miRNA target sites.  
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Figure 6: Graphical representation of CAGE tag enrichment within Danio rerio 3’ UTRs at 
early embryonic stages – showing number of CAGE tags against relative position of 5’ 
miRNA seed site. Produced by Chirag Nepal. 
 
 
Figure 6 shows peak CAGE tag enrichment at 15-20bp downstream of the miRNA 
seed sites, potentially linked to miRNA cleavage events (miRNA themselves being 
22bp in length).  
 
It is plausible to suggest (hypothetically, not-supported by prior published data) 
that this CAGE tag enrichment is indicative of functional miRNA-mRNA 
interactions and, if so, there is a potential for CAGE tag enrichment to be used in 
conjunction with current miRNA target prediction methods to improve prediction 
specificity. Coupled with the bioinformatics data above suggesting the potential for 
CAGE tags to be indicative of miRNA-mRNA interactions, there is theoretical 
plausibility supporting such a scenario: essentially, CAGE capping ‘could’ occur at 
miRNA induced cleavage sites within mRNA sequences, as a by-product of the 
cleavage process itself (theoretical conjecture) which could act to delay 
14 
 
degradation at the point of RISC interaction, allowing recapping of the RNA and 
production of the CAGE tag. In addition to this, comparison of CAGE predicted 
target site data in wild-type zebrafish embryos against MZ-Dicer mutant zebrafish 
embryos (lacking the Dicer enzyme and as such, not exhibiting miRNA 
processing) shows a predicted lack of CAGE tag enrichment at suspected target 
sites – suggesting that CAGE tag enrichment may indeed be indicative of miRNA 
cleavage events.  
 
 
Figure 7: Represents CAGE tag enrichment within the zebrafish genome at 24 hpf in two 
conditions - A: WT embryos at 24 hours, B: MZ Dicer knockout embryos at 24hpf. X axis 
represented as nucleotide distance from seed site (Produced by Chirag Nepal). 
 
 
 
 
 
Figure 7 shows CAGE tag enrichment seen in wild type Danio rerio embryos at 
24hpf as compared to a lack of enrichment in MZ Dicer knockout embryos at 
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24hpf. MZ Dicer knockout embryos lack Dicer, a critical component in maternal 
miRNA mediated degradation and results in a lack of any miRNA function (Abrams 
and Mullins, 2009). This somewhat supports the suggestion that CAGE tag 
enrichment within 3’ UTRs may indicate a miRNA cleavage event and miRNA 
target site. 
 
These findings however, are preliminary – and it remains unclear as to whether 
CAGE tags seen at miRNA target sites within 3’ UTRS are the result of miRNA 
mediated degradation, a predictor of miRNA mediated direction, or even as an 
artefact of computational analysis. In an effort to shed some light on this finding, it 
is the goal of my project to identify an ideal CAGE predicted miRNA target site and 
experimentally validate the site as a ‘true’ target site. As such, my project can be 
somewhat divided into three parts; First, computational analysis of RNA 
sequencing data and CAGE data of the Danio rerio (zebrafish) genome database 
to determine ‘true’ miRNA target site predictions (performed almost entirely by 
Chirag Nepal of the University of Copenhagen), and an ideal predicted target for 
experimental validation.  Second, the design and trial of a protocol to successfully 
validate a predicted miRNA target site (using pre-validated target genes). Finally, 
experimental validation of a previously unverified miRNA target site predicted to 
be a ‘true’ target based on CAGE prediction data, and creation of the mRNA 
constructs that allow such validation. 
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1.8 Danio rerio: Zebrafish in genomics 
 
The proposed method for the validation of bona fide miRNA target sites involves 
following the expression patterns of predicted target genes during zebrafish 
embryo development of both wild type (WT) and mutant (MUT) embryos. 
Zebrafish function well as a model vertebrate organism for the study of 
development, with a small size and optical transparency (Figure 8) allowing high 
resolution imaging of live embryos at various stages. This is coupled with a 
relatively high embryo production rate, and relatively fast embryo growth, allowing 
the investigation into multiple stages of development over short periods of time 
(Lieschke and Currie, 2007).  
 
 
Figure 8: Image showing zebrafish embryo transparency, and easily achievable 
microscopic resolution 
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(http://www.zebrafishlab.be/sites/default/files/styles/media_gallery_large/public/embryos-
7.jpg).  
 
 
Such characteristics should enable the use of fluorescent proteins to act as 
markers linked to specific genes for quantification of gene expression (Villefranc et 
al., 2007, Finley et al., 2001). This is a core concept of my project; with the 
proposed mechanism for validation of CAGE predicted miRNA target sites relying 
on the specific binding characteristics of miRNAs to their cognate mRNA 
transcripts. As mentioned previously, many factors affect miRNA binding to target 
mRNA transcripts, an important factor of which is strict Watson-Crick base-pairing 
(Valencia-Sanchez et al., 2006). As such, if a specific miRNA target is predicted 
on a certain gene, one would expect miRNA mediated suppression of this gene, 
and degradation of mRNA transcripts. If, however, the cognate mRNA sequence 
complementary to the miRNA is manipulated to contain base mismatches against 
the RNA, then presumably (considering the site a ‘true’ miRNA target), miRNA 
mediated degradation shall not occur, and accumulation of the mutated gene shall 
arise (Doench and Sharp, 2004). As such, the rationale behind this project is to 
identify unique CAGE predicted miRNA target sites within the early zebrafish 
developmental stages and to design and create fluorescent protein linked RNA 
constructs incorporating two versions of such a predicted miRNA target site – A 
wild type unmodified target site, and a mutant target site containing base 
mismatches. Assuming natural production of the targeting miRNA in early 
zebrafish stages, one could inject the aforementioned constructs into newly 
fertilised zebrafish embryos and measure gene expression (via linked fluorescent 
probe) throughout development (Giraldez et al., 2006). If the target site 
incorporated into the injected RNA construct is legitimate, then one would expect 
18 
 
miRNA mediated suppression and degradation of gene transcripts (and relatively 
low expression of fluorescent marker) (Bartel, 2004, Flynt and Lai, 2008, 
Wakiyama et al., 2007). The mutant construct on the other hand, by way of 
induced base mismatches within the identified target site should show (relative) 
accumulation of gene transcripts (and relative abundance of fluorescent marker) 
via lack of miRNA mediated repression. On the other hand, if the predicted target 
site has, in fact, been wrongly predicted, one would expect no difference in the 
expression of the injected RNA construct, and similar levels of fluorescence in 
both the wild type and mutant treatment groups. In addition to wild type and 
mutant RNA probes, a control fluorescent probe shall have to be used in 
conjunction with the probe linked to a predicted miRNA target. This probe should 
be linked to an invariant gene, one not targeted for miRNA mediated degradation 
(at the least, not in early development stages up to 72hpf) (Stürzenbaum and Kille, 
2001). As such, this probe would act as a control for the amount of construct 
injected into individual embryos (to which the treatment probe can be normalised 
against), and as a potential indicator of non-specific / non-miRNA mediated 
degradation (if such results arose that may suggest this). 
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OBJECTIVES 
 
The main and principal goal of this short research project was to determine if 
CAGE data of the Danio rerio genome has the potential for use in the prediction of 
true miRNA target sites within zebrafish. The determination of the usefulness of 
CAGE data in this capacity was performed through multiple steps. In chronological 
order, these steps comprised: 
 
 The identification of maternally inherited and early-stage active miRNAs in 
the zebrafish. 
 Selection of prospective Danio rerio genes targeted by identified maternal 
miRNAs for use in the experimental validation of CAGE predicted miRNA 
target sites. 
 Experimental validation of a novel CAGE predicted miRNA target site as a 
‘true’ miRNA target site. 
 Evaluation of CAGE as an assistive tool in the prediction of bona fide 
miRNA target sites within zebrafish. 
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MATERIALS & METHODS 
 
 
 
3.1 Selection of candidate target genes for experimental 
validation of CAGE predicted miRNA targeting 
 
The selection of candidate genes for experimental validation of CAGE predicted 
miRNA target sites was performed through the use of multiple RNA libraries and 
RNA sequencing data gained from previous studies into RNA expression within 
zebrafish, both temporal and spatial (Yao et al., 2014, Wei et al., 2012). These 
libraries, containing expression data of both early developmental stage mRNA and 
miRNA expression were used in conjunction with the CAGE data gleaned from 
Nepal et al.’s 2013 research paper. The data from these projects were uploaded 
into custom tracks on the UCSC Genome Browser (http://genome.ucsc.edu/) for 
analysis and comparison side by side. 
 
3.1.1 Candidate target gene criteria 
 
The selection of Danio rerio candidate genes for experimental validation of CAGE 
predicted miRNA target sites is determined by these main criteria: 
 The gene must be expressed maternally (i.e. Pre-MBT; unfertilised egg up 
to 64 cell stage and ≥5 transcripts per million (tpm)). 
 The gene must have at least one CAGE predicted maternal miRNA target 
site present within the 3’UTR pre-MBT (preferably only one). 
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 As far as possible, this predicted miRNA target site should not overlap with 
any other predicted or known miRNA target sites present pre-MBT (i.e. 
have physically overlapping target recognition sites) in an attempt to ensure 
that any change in expression is due to the miRNA in question and not due 
to a different, potentially confounding miRNA . 
 The candidate gene should show an expression pattern consistent with that 
of a gene affected by the maternal miRNA predicted to be targeting it. 
 
3.1.2 Identification of maternal miRNAs 
 
To identify maternal miRNAs and potential candidate genes for the validation of 
predicted miRNA target sites, certain filters were applied to RNA library data: 
miRNAs that are inherited maternally and significantly active pre-MBT are 
identified, using RNA expression data from previous work into RNA expression 
during early zebrafish development (Yao et al., 2014, Wei et al., 2012).  
 
3.1.3 Identification of potential gene targets 
 
Identification of potential miRNA gene targets involves the identification of any 
CAGE predicted target site of miRNAs identified as candidates for experimental 
validation in 2.1.2. These CAGE predicted target sites are reviewed to identify only 
target sites showing an expression pattern consistent with maternal miRNA 
degradation according to the RNA library expression data. Specifically, target 
genes were filtered to include only those that were expressed in all three maternal 
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stages (≥5 tpm), and whose expression levels were higher (at least ≥1.5 fold in at 
least two pre-MBT stages) during Pre-MBT stages as compared to MBT stages. 
Any potential maternal miRNA gene targets meeting the criteria for use are then 
manually viewing in the UCSC genome browser to both confirm expression 
patterns throughout early development, and to identify ideal candidates with no or 
few conflicting CAGE predicted miRNA target sites during early development. 
 
3.1.4 Proof of concept for experimental miRNA target site 
validation 
 
To validate the proposed experimental method for confirming the presence of a 
‘bona fide’ miRNA target site, a proof of concept experiment is performed on a 
known and previously validated miRNA target site. The cxcr7b gene was chosen 
as a previously verified miRNA target of miR-430, a maternally inherited miRNA 
(Staton et al., 2011). Experimental validation of cxcr7b as a miR-430 target 
required multiple steps: 
 The design, creation and purification of two gene constructs; one construct 
containing the wild type cxcr7b seed region to which miR-430 is targeted, 
and a second, mutant construct, containing base mismatches within the 
seed region to prevent miR-430 targeting and miR-430 mediated mRNA 
degradation. Both constructs are designed with an mCherry reporter for 
mRNA degradation and a CFP reporter for control of RNA injection 
amounts and retrospective normalisation of mCherry values. 
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 Microinjection of the RNA constructs into 1 cell stage Danio rerio embryos 
of two groups; wild type (WT), or mutant (MUT) RNA. 
 Growth of the embryos to 72h.p.f. 
 Random selection of embryos for automated fluorescent imaging and 
quantification of mRNA via the measurement of both mCherry and CFP 
fluorescence. 
 Optional: Further quantification of mRNA via RT-qPCR 
 Comparison of the relative cxcr7b expression between WT and MUT 
groups. 
 
3.1.5 Design of mRNA constructs for use in experimental 
validation 
Note: The design, production and implementation of both the cxcr7b WT/MUT and the 
nploc4 WT/MUT RNA sequences in the laboratory for microinjection into zebrafish 
embryos follow identical procedures and, as such, only the design and production of the 
nploc4 constructs (being the more important component of this project) shall be detailed. 
 
Design of the RNA constructs for use in the validation experiments was performed 
in Serial Cloner 2.5, a tool allowing graphical representation of DNA constructs 
with virtual construction, fragmentation, sequence alignment etc. 
(http://serialbasics.free.fr/Serial_Cloner.html). All constructs are designed within a 
pCS2 vector; owing to its high level of transient expression in vertebrate cells and 
ability for in vitro RNA synthesis of sequences cloned into one of the available 
polylinker sites 
(http://www.xenbase.org/reagents/vectorAction.do?method=displayVectorSummar
y&vectorId=1221270): 
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Figure 9: Serial Cloner graphical map of the nploc4 wild type RNA construct, designed 
within a pCS2 vector. ‘A’ represents the WT nploc UTR sequence. 
 
 
Figure 10: Serial Cloner graphical map of the nploc4 mutant RNA construct, designed 
within a pCS2 vector. ‘B’ represents the MUT nploc4 UTR sequence. 
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Figures 9 & 10 represent graphical maps of the designed pCS2 plasmid vectors, 
containing multiple key features. Importantly, the vector contains an mCherry 
coding sequence for the production of red fluorescent protein as a marker for gene 
expression (Villefranc et al., 2007). Additionally (though not shown on the 
sequence map) this pCS2 vector contains multiple endonuclease restriction sites 
for linearization of the plasmid at specific sites for incorporation of the nploc4 gene 
sequence. Further, the vector contains CMV and SP6 promoter sequences for 
relatively high expression of the nploc4 WT/MUT gene (Schmidt et al., 1990) 
(Melton et al., 1984) and an SV40 polyA site for polyadenylation and stability of 
the mRNA (Connelly and Manley, 1988) .On top of this, the vector contains 
ampicillin resistance genes for selection of correctly transfected cells during 
transformation (Glover, 2013). Both the WT and MUT constructs contain all of 
these key features, and only differ in the nploc4 3’UTR, in which the WT construct 
contains the original sequence complementary to the miR-430 seed region 
(allowing miR-430 mediated degradation), and the MUT 3’UTR contains base 
mismatches introduced into this sequence (to prevent miR-430 mediated 
degradation), as seen in Figure 11 (which results in a 1 bp plasmid size difference, 
5388bp (WT)[A in figure 9] compared to 5387bp (MUT)[B in figure 10]). 
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Figure 11: A local sequence alignment representing a section of the nploc4 3’UTR 
contained within the pCS2 vector. The only difference between the WT and MUT 
constructs is that of base mismatches between bases 1131 and 1154 within the nploc4 
sequence, introduced to prevent predicted miR-430 mediated degradation of the mutated 
sequence. 
 
 
 
Both the nploc4 WT and nploc4 MUT 3’UTR sequences were ordered as 
oligonucleotide forward (FP) and reverse (RP) primers for use in the production of 
nploc4 WT / MUT RNA via In-Fusion HD Cloning (Table 4). 
 
 
Primer Name MW Tm(°C) µg nmol GC% µl for 20 µM 
  
     
  
nploc4_3UTR_FP 11043 79.7 322.2 29.1 50.0 1459 
nploc4_3UTR_RP 12475 75.6 325.3 26 42.5 1304 
nploc4_m430DL_FP 13129 89.5 366 27.8 58.1 1394 
nploc4_m430DL_RP 13177 85.2 420.6 31.9 53.4 1596 
 
Primer Name Sequence (5-3) 
  
     
  
nploc4_3UTR_FP AGTGAGTCGTQTTQCAACCCCAATGAACCCGGGCTA 
nploc4_3UTR_RP 
CATGTCTGGATCTACGTAAGAAAGTAGATGTGGTGATGT
G 
nploc4_m430DL_
FP 
TCAGTTGAAGTGGTCTATGCGACCGAAGCTCCTGCCACC
CCCA 
nploc4_m430DL_
RP 
GTCGCATAGACCACTTCAACTGAGTCCCAGAATGCACTG
GGCT 
Table 2: Properties of the In-Fusion primers ordered for the nploc4 WT / MUT fragment 
generation. GC% content within 40-60% and primer pair Tm within 5°C of each other. 
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3.2 Production of mRNA constructs for use in experimental 
validation 
 
The first step towards creation of an injectable RNA construct involved 
linearization of the pCS2 vector via restriction digestion with SnaBI (digesting 
immediately before the SV40 promoter sequence). A 50 µl reaction mixture was 
made containing 10 µl pSC2 plasmid, 5ul 10x reaction buffer, 2 µl SnaBI 
restriction enzyme (1 unit/µl) and 33 µl dH2O, gently pipetted to thoroughly mix 
and incubated at 37°C overnight (~20 hours) to produce a 4806bp linearized 
plasmid (correct digestion and lack of contamination confirmed through gel 
electrophoresis of sample). 
 
 
3.2.1 pCS2 Vector Linearization 
 
Materials: 
10 µl pSC2 plasmid 
5 µl 10x buffer 
2 µl SnaBI enzyme (1 unit/µl) 
33 µl dH2O 
1 ml centrifuge tube 
37°C Incubator 
 
28 
 
3.2.2 PCR amplification of desired WT / MUT fragments  
 
Materials: 
2 µl template DNA 
15 µl HD Buffer 
6 µl dNTP mixture 
0.75 µl HD polymerase (2.5 units/µl) 
47.5 µl dH2O 
1.25 µl nploc4 WT 3’UTR FP 
1.25 µl nploc4 WT 3’UTR RP 
0.625 µl nploc4 MUT 3’ UTR FP 
0.625 µl nploc4 MUT 3’ UTR RP 
Geneflow Thermocycler 
 
Following plasmid linearization, PCR amplification is performed to amplify the 
insert DNA of both WT and MUT 3’UTR constructs. All reagents are thawed on ice 
before a main reaction mixture is prepared comprising 2 µl template DNA, 15 µl 
HD Buffer, 6 µl dNTP mixture, 0.75 µl HD polymerase and 47.5 µl dH2O (total 
71.25 µl) as the base for 3 x 25 µl reaction mixtures. 
23.75 µl of this reaction mixture was taken for each of three amplification 
reactions: 
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1. 0.625 µl WT 3’UTR FP + 0.625 µl WT 3’UTR RP (+23.75 µl mix) [WT] 
2. 0.625 µl WT 3’UTR FP + 0.625 µl MUT 3’UTR RP (+23.75 µl mix) [F1] 
3. 0.625 µl MUT 3’ UTR FP + 0.625 µl WT 3’UTR RP (+23.75 µl mix) [F2] 
 
Each reaction mixture was pipetted into separate PCR tubes, mixed and 
centrifuged briefly (10s) before undergoing the following PCR protocol: 
 
Repeat cycles Temp (°C) Times (s) Cycles 
  
  
  
  94 120 1 
  94 20 30 
  55 15 30 
  ↻ 72 45 30 
  72 30 1 
  10 ∞ 1 
 
 
Once the PCR protocol is completed, a sample of each product is taken and run 
through gel electrophoresis, followed by spectrophotometric analysis for 
confirmation of desired product amplification and purity (end product consists of 
20ul amplified fragment samples).  
 
3.2.3 Gel Electrophoresis 
 
Materials: 
0.3g pure agarose powder 
30ml TAE buffer 
3 µl 100bp ladder marker 
2 µl product sample (x3) 
1 µl ethidium bromide (x3) 
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1 µl loading dye (x3) 
 
1% agarose gels (30ml TAE, 0.3g Agarose powder) containing 1 µl ethidium 
bromide were used for electrophoresis. A 2 µl sample of each product was taken 
and loaded with 1 µl loading dye and 1 µl nuclease free H2O after thorough 
mixing. This was compared against 3 µl of 100bp ladder as a marker. The gel was 
run at 80V for 40 minutes before visualisation under UV light to confirm purity of 
expected products (Figure 12).  
 
 
 
Figure 12:  UV visualisation of 1% agarose gel electrophoresis to determine correct 
plasmid amplification, insert ligation, and to confirm lack of contamination. Lane 1: F1. 
Lane 2: F2, Lane 3: WT. 100bp ladder was used as a marker. 
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3.2.4 Spin column purification 
 
Materials: 
In-Fusion HD cloning kit including: 
80 µl dH2O (making up to 100 µl) per sample 
200 µl NTI Binding Buffer per sample 
750 µl NT3 washing buffer per sample 
 
Following this, the products of the previous PCR amplification (F1, F2 and WT) 
were purified via spin-column purification (plasmid DNA clean up) – each product 
was made up to 100 µl with dH2O, followed by the addition of 200 µl binding buffer 
NTI in a spin-column. Each sample was then centrifuged at 11000g for 30s before 
being washed with 750 µl NT3 washing buffer. Each sample is spun for a further 
30s at 11000g to remove the NT3 buffer, further spun at 11000g for 30s for 
improved removal of any ethanol that may remain from the NT3 buffer, and finally 
the DNA for each sample is eluted with 30 µl NE buffer via a 60s 11000g spin. The 
purified product for each sample is then kept and used for the In-Fusion cloning 
procedure. 
 
Taking the purified samples of WT, F1 and F2, three reactions are set up for in 
fusion cloning to produce an nploc4 WT 3’UTR incorporating plasmid, an nploc4 
MUT 3’UTR incorporating plasmid and a Control sample. 2 µl linearized vector, 6 
µl HD polymerase enzyme and 13 µl dH2O is mixed to produce a 21 µl reaction 
mixture to be split 3 ways for each reaction: 
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7 µl reaction mixture + 1 µl nploc4 WT 3’UTR + 2 µl dH2O (WT) 
7 µl reaction mixture + 1.5 µl nploc4 F1 MUT 3’UTR + + 1.5 µl nploc4 F2 MUT 
3’UTR (MUT) 
7 µl reaction mixture + 3 µl dH2O (control) 
 
Each reaction mixture is pipetted into separate 1ml centrifuge tubes and incubated 
for 15 minutes at 50°C before being stored at -20°C until transformation.  
 
3.2.5 Transformation of electrocompetent E. coli cells with 
purified PCR fragments 
 
Materials: 
Electrocompetent E. coli cells 
In-Fusion transformation reaction mixture 
LB agar 
Ampicillin (100 µg/µl) 
 
Pre-prepared electrocompetent E. coli cells are used for the transformation of the 
three purified products: nplco4 WT, nploc4 MUT and Control plasmids. 1µl of each 
reaction product is placed into reaction tubes with 2.5 µl in-fusion reaction mixture 
and made to 100 µl with electrocompetent E. coli cells incubated on ice for 5 
minutes. Following this, each reaction mixture was spread onto ampicillin 
containing agar plates and incubated at 37°C for selection of ligated plasmids. 
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Following incubation, 5 colonies from each of WT and MUT reactions were taken 
(as expected, control plasmids results in few colonies) and transferred into falcon 
tubes containing 5ml of LB agar and 5 µl of ampicillin. These mixtures were then 
further incubated at 34.5°C in an agitating incubator for growth and further 
selection. 
 
3.2.6 Selection of desired plasmids 
 
Materials (per PCR reaction): 
1.6 µl dNTP mix 
4 µl HD Buffer 
0.2 µl TAC polymerase 
14 µl dH2O 
0.1 µl T6 Primer 
0.1 µl P7 Primer 
1 µl reaction mixture of each colony to be tested for insert 
 
Following incubation and bacterial growth of transformed cells, 1 ul of each 
reaction mixture is taken for selection of bacteria with desired plasmid insert 
incorporation (5 WT and 5 MUT). TAC polymerase rather than high fidelity 
polymerase was used in the PCR amplification of each colony: 
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Repeat cycles Temp (°C) Time (s) Cycles 
  94 300 1 
  94 30 30 
  55 40 30 
↻  72 90 30 
  72 300 1 
  12 ∞ 1 
 
Following amplification, each PCR product was run on an electrophoresis gel (as 
per previous protocol – 1% agarose, 80v, 40 minutes) to identify colonies with 
correctly incorporated WT and MUT UTR inserts within the vector. 
 
3.2.7 Isolation and purification of DNA from bacterial cells 
 
Purification of the WT 3’ UTR and MUT 3’ UTR plasmids was performed through 
the use of the Qiagen plasmid mini-kit following this protocol: 
 Cells thawed on ice and collected by centrifugation for 15 minutes at 6000g 
and 4°C 
 Cells suspended in 0.5ml P1 resuspension buffer (50mM Tris-Cl, 
10mMEDTA, 100µg/mL RNase A) 
 0.5ml of P2 lysis buffer (200mM NaOH, 1% SDS) added, with immediate 
mixture via tube inversions and incubation at room temperature for 5 
minutes 
 0.5ml P3 neutralisation buffer (3M potassium acetate)  added, with 
immediate mixture via tube inversions and incubation on ice for 5 minutes 
 Centrifugation of each mixture for 10 minutes at 11000g 
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 Application of the centrifugation supernatant to a Qiagen purification tip for 
complete filtering 
 Addition of 2 x 2ml QC wash buffer (1M NaCl, 50mM MOPS, 15% 
isopropanol) for complete filtering 
 Addition of 0.8ml QF elution buffer (1.25M NaCl, 50mM Tris-Cl, 15% 
isopropanol) with the eluate collected 
 DNA within eluate precipitated with the addition of 0.56ml isopropanol and 
centrifugation at 11000g for 30 minutes at 4°C 
 
With the DNA purification complete, both the pCS2 WT UTR and pCS2 MUT UTR 
solutions are further tested for correct plasmid sequences via restriction digestion 
and gel electrophoresis for identification of expected restriction fragments. 
 
3.3 Confirmation of pCS2 WT UTR and pCS2 MUT UTR plasmids 
via restriction digestion and gel electrophoresis 
 
Materials (per reaction): 
0.5 µl BamHI  
0.5 µl XbaI 
1 µl SnaBI 
2 µl CutSmart buffer (50mM Potassium Acetate, 20mM Tris-acetate, 10mM 
Magnesium Acetate, 100μg/ml BSA) 
11 µl dH2O 
5 µl DNA sample 
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Samples of both the pCS2 WT UTR and pCS2 MUT UTR purified DNA were 
digested with SnaBI, BamHI and XmaI restriction endonucleases for 40 minutes at 
37°C followed by gel electrophoresis on a 1% agar gel (as per previous protocol). 
Assuming correct plasmid restriction, 3 fragments were expected to be obtained 
for both WT and MUT plasmids. 
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pCS2 nploc4 WT UTR expected restriction digestion: 
 
 
 
Figure 13: Serial cloner virtual restriction digestion of the pCS2 nploc4 WT UTR 
containing plasmid with BamHI, SnaBI and XmaI resulting in the generation of three 
fragments. 
 
pCS2 nploc4 MUT UTR expected restriction digestion: 
 
 
 
Figure 14: Serial cloner virtual restriction digestion of the pCS2 nploc4 MUT UTR 
containing plasmid with BamHI, SnaBI and XmaI resulting in the generation of three 
fragments. 
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The fragments generated shall differ only in 1bp of one fragment (566 bp vs 567 
bp of the XbaI to SnaBI cut) representing the 1 bp WT / MUT fragment difference 
(Figures 13 & 14). 
  
 
3.4 RNA synthesis of purified wild type and mutant pCS2 
plasmids 
 
Materials (per reaction): 
Linearization: 
30 µl plasmid 
1 µl NotI 
10 µl CutSmart buffer 
9 µl H2O 
 
Transcription: 
10 µl 2x NTP/CAP buffer solution 
2 µl 10x Reaction Buffer 
2 µl Enzyme mix (RNA polymerase, RNase inhibitor) 
2 µl nuclease free H2O 
4 µl linearized plasmid 
An mMESSAGE mMACHINE transcription kit 
(http://tools.lifetechnologies.com/content/sfs/manuals/cms_055516.pdf) is used for 
in vitro synthesis of MUT / WT capped RNAs. First the purified plasmids are 
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digested with NotI restriction endonuclease for 3 hours at 37°C in preparation for 
transcription. 
Following linearization, the transcription reaction mix is assembled at room 
temperature and mixed thoroughly, followed by brief 10s centrifugation. The 
reaction mixture is then incubated at 37°C for one hour. 
 
Subsequent to incubation and RNA synthesis, recovery of the RNA is performed 
through phenol:chloroform extraction and isopropanol precipitation. 
 
Materials: 
115 µl nuclease free H2O 
15 µl ammonium acetate stop solution 
20 µl transcription reaction mix 
150 µl phenol:chloroform 
150 µl chloroform 
150 µl isopropanol 
115 µl nuclease free H2O and 15 µl ammonium acetate stop solution is added to 
the 20 µl transcription reaction mixture following incubation and mixed thoroughly. 
This is followed by phenol:chloroform extraction with equal volume 
phenol:chloroform and centrifugation at 10,000 g for 5 minutes at room 
temperature. The aqueous phase is collected, transferred to a fresh tube and 
further extracted with equal volume chloroform at 10,000 g for 5 minutes. Again, 
the aqueous phase is collected and transferred to a fresh tube before being 
precipitated with 1 volume isopropanol and chilled on ice for 15 minutes. Finally, 
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the mixture is centrifuged at 15,000 g for 15 minutes at 4°C and the purified RNA 
pellet is dried and resuspended in 60 µl of DNase free water for storage of the 
RNA at -20°C. 
 
3.5 Confirmation of RNA purity via gel electrophoresis and 
spectrophotometry 
 
One final gel electrophoresis gel is run to confirm purified RNA products and to 
ensure lack of contamination (as per previous protocol). In addition, 
spectrophotometric analysis of nploc4 WT / nploc4 MUT RNA samples is 
undertaken to ensure lack of contamination and confirm RNA concentration. 
Both RNA mixtures are made up to 150 ng/µl via dilution in nuclease free H2O and 
stored at -20° until use in embryo microinjection. 
 
3.6.1 Embryo collection and RNA injection 
 
Materials: 
Breeding tanks 
Breeding tank dividers 
100mL petri dishes 
Pre-prepared RNA for miRNA target of study (nploc4 / cxcr7b) 
CFP RNA 
MINJ-1 Tritech Research microinjection system 
E3 + Gentamycin media 
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Prior to embryo collection, dividing barriers within each breeding tank are removed 
and the tanks placed at an angle (~30°) to simulate a shallow/deep water gradient. 
The fish are then left to lay and fertilise the embryos before collection (~20 
minutes). 
 
Upon collection, embryos are counted, divided equally into treatment groups and 
pipetted onto petri dishes for RNA injection. Excess fish water is removed via thin-
tipped pipette and the embryos arranged into a one cell high layer in preparation 
for injection (note: RNA injection is best done at the 1 cell stage, and as such, 
embryo collection, preparation and injection should be done as quickly as 
possible). The embryos are then micro-injected with ~2nl of ~30ng/ µl RNA (Wild 
Type + CFP / Mutant + CFP, dependent upon group). Microinjection is performed 
using a MINJ-1 Tritech Research microinjection system. 
 
First, a few microlitres of the relevant RNA construct is loaded into the 
microinjection needle, the needle is attached to the needle holder and fastened in 
place. The micro-injector gas valves are then loosened to allow gas-powered 
microinjection, followed by cutting the tip of the needle with a scalpel to allow 
injection (requires a good cut to produce a needle tip that is not too long and 
flexible, and yet not too short and thick). Viewing the embryos under a microscope 
(approximately 15x magnification), the needle is manually controlled to deliver a 
single ‘burst’ (~2nl) of injected RNA (via foot pedal) into the yolk of the embryo 
(with a smooth and ‘clean’ stabbing motion through the chorion). This is repeated 
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for all embryos within the petri dish, with water tension preventing the embryos 
from moving. Once completed, the embryos are resubmerged in fish water and 
stored in a 27.5°C incubator while the next RNA construct is delivered to the next 
treatment group with a repeat of the above procedure. 
 
Once all injections are complete, embryos are submerged in solution containing 
E3 media and gentamycin, and stored within a transparent petri dish in an 
incubator at 28.5°C. The embryos are periodically checked throughout growth to 
replace media, remove dead or deformed cells, to perform dechorionation and for 
the addition of phenylthiourea (PTU) to remove pigmentation before examination 
and imaging (if applicable). 
 
3.6.2 Fluorescence imaging and mRNA quantification 
 
Materials: 
Olympus Scan^R IX 81 microscope 
Custom made 96 well plate 
Tricaine mesylate 
Broad (cut) tipped pipette 
 
 
Embryos undergoing automated fluorescent imaging for determination of RNA 
quantification are dechorionated and treated with PTU at around 8hpf (to avoid 
potential developmental defects that may be induced if applied earlier) to clear 
pigmentation and allow visualisation of tissue specific fluorescence. 
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Fluorescence imaging is undertaken using an Olympus Scan^R IX 81 fluorescent 
microscope, capable of automated imaging of 96 well plates at multiple 
wavelengths. In this case, embryos are imaged through brightfield (BF), red 
fluorescent protein (RFP) and cyan fluorescent protein (CFP) filters. Following 
injection and growth to the relevant stage (72 hpf), embryos from each treatment 
group (be it cxcr7b WT / MUT or nploc4 WT / MUT) are screened pre-visualisation 
to ensure uptake and dissemination of injected RNA via CFP screening. Of those 
embryos positive for injected RNA incorporation, 48 embryos of each treatment 
group are randomly selected for anaesthetisation with a drop of tricaine mesylate 
(MS-222) within a petri-dish of E3 media and gentamycin. Following anaesthesia, 
each embryo is pipetted into a separate well within a 96-well plate (using a cut-
tipped pipette, and along with 200 µl of media) and orientated in a lateral position 
(with the aid of a custom pin-prick induced hole at the bottom of each well to 
accommodate the yolk sac bulge) at the centre of each well (Figure 15). 
 
 
 
Figure 15: An example of embryo orientation with a well of a 96-well plate. Each embryo 
is orientated in a lateral position, as close to the centre of the plate well as possible to 
reduce variability between each embryo when imaged automatically. 
 
 
 
It is important to correctly orientate each embryo in a lateral position and as 
similarly as possible to reduce variation in imaging due to improper orientation. 
The Scan^R automated imaging system can somewhat adjust to minor deviations 
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in orientation, but this is best minimised for consistent imaging and results. 
 
Once all 96 well plates are loaded (48 WT / 48 MUT), and the embryos correctly 
orientated, the plate can be loaded on the Scan^R microscope for automated 
imaging. The Scan^R acquisition software enables the use of multiple channels for 
simultaneous BF, RFP and CFP imaging at multiple z planes for each embryo. 
Automated adjustments are made for each embryo to maintain focus and provide 
images along the z plane. These images are then compiled to create a projected 
‘3d’ image of each embryo (for each channel) (Figure 16). 
 
 
Figure 16: A Scan^R acquisition image representing the focal points used to identify the 
embryo and in conjunction with zMiner, assign specific sectors to various compartments 
of the embryo (Yolk, Eye, Skin, Brain, Cerebellum, Heart, Notochord and Spinal Cord). 
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Following imaging, the Scan^ acquired images are processed through zMiner: a 
computer program designed to both identify distinct regions within each embryo 
(Yolk, Eye, Skin, Brain, Cerebellum, Heart, Notochord and Spinal Cord), and to 
calculate relative fluorescent expression in each of these regions (Gehrig et al., 
2009). As such, relative values for tissue specific fluorescent expression of both 
mCherry and CFP are obtained for each embryo for use in quantitative analysis of 
RNA expression between treatment groups as a representation of miRNA 
mediated degradation. mCherry expression is representative of relative target 
gene expression changes between treatment groups (expression is relative to 
degree of miRNA mediated mRNA repression and degradation) (Giraldez et al., 
2006). CFP meanwhile, acts as a normalisation control for deviances in RNA 
injection amounts between embryos (expression is relative to injection amount due 
to no degradation within the embryo) (Gong et al., 2001), acting as an alternative 
to GFP.  
 
3.6.3 RT-qPCR and mRNA quantification  
3.6.3a RNA extraction and purification 
Materials: 
Shield stage RNA injected embryos 
Trizol reagent RNA mini kit 
Chloroform 
100% ethanol 
70% ethanol 
Homogenizing kit 
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RNase free centrifuge tubes 
 
As an alternative to fluorescent imaging, mRNA quantification of embryos can be 
performed through the use of real time reverse transcription quantitative 
polymerase chain reaction (Gehrig et al., 2009). For this procedure, the same 
RNA constructs are used for injection of the zebrafish embryos, and the breeding, 
injection and growth procedures are all the same as previously used, up to ~6hpf 
(shield stage) of embryo growth. Following dechorionation and clearing of dead 
and deformed cells, embryos at shield stage (~6hpf, if embryo stages vary 
between treatment groups, incubation temperature can be adjusted in an effort to 
normalise stage progression, with colder temperatures slowing progression and 
vice versa) are anaesthetised in MS-222 in preparation for RNA extraction via 
Trizol RNA purification. 
 
First, the embryos are homogenised in 1mL of Trizol reagent and a tissue 
homogeniser and allowed to incubate at room temperature for 5 minutes. Next, 
RNA is isolated from the homogenate via the addition of 0.2 ml of chloroform and 
incubation at room temperature for 3 minutes after mixing. The solution is then 
centrifuged for 15 minutes at 12,000 g and 4°C, and ~600 µl of the colourless 
aqueous phase containing RNA is collected and transferred to a new centrifuge 
tube. Following this, 600 µl of 70% ethanol is added to complete phase 
separation. 
 
47 
 
Following phase separation, 700 µl of the RNA / 35% ethanol mixture is 
transferred to a spin cartridge within a centrifuge tube and further centrifuged at 
12000 g for 15 minutes at 4°C. Subsequently, 700 µl of Trizol wash buffer I is 
added to the spin cartridge and centrifuged for 15s at 12000g and room 
temperature. The wash buffer I flow-through is discarded and 500 µl Trizol wash 
buffer II added with further centrifugation at 12,000 g and room temperature for 
15s. Further centrifugation at 12,000 and room temperature is performed for 1 
minutes to dry the spin cartridge membrane before elution of the column with 3 x 
100 µl DNase free water and collection of the flow-through in the centrifuge tube. 
The tube is then centrifuged one final time at 15,000 g for 2 minutes at room 
temperature to obtain a final solution containing the isolated RNA. 
The isolated RNA is then stored in 75% ethanol at -20°C until further use. 
 
3.6.3b RT-qPCR 
 
Materials: 
BioRad iQ5 Light Cycler 
RT Buffer 
dNTP Mix 
RNase Inhibitor 
Reverse Transcriptase 
DEPC-H2O  
PCR Buffer 
PCR primers 
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TAQ polymerase 
 
A reverse transcription quantitative polymerase chain reaction was used as a 
secondary measurement of nploc4 mCherry expression differences in wild type 
and mutant embryos using a standard RT-qPCR protocol. First, multiple primers 
were designed and created for effective quantification of the gene of interest 
(mCherry linked nploc4). Primer pairs were designed targeting (a) nploc4 mCherry 
1, (b) nploc4 mCherry 2 and (c) SF3A2 (relative control) (Table 5). The mCherry 
primer pairs are for use in quantifying nploc4 gene expression, while the SF3A2 
primer pair is for use as a relative control – targeting an invariant exogenous gene 
for comparison of relative expression change. Considerations need to be made 
alluding to the design of suitable RT-PCR primers. Suitable primer pairs should be 
designed so that the target amplicon is no longer than 200bp in length. A Tm of 
~60°C is preferable, but importantly, each primer pairs Tm should not differ by 
more than ~3°C. In addition to these factors, it is best if primers span an exon-
exon junction, to prevent amplification of contaminating genomic DNA, and best if 
the primer GC content is ~50-60% for product stability. Finally, the lower the self 
complementarity between primers the better, to minimise primer-dimer formation 
and lack of efficiency (Brownie et al., 1997). 
 
 
 
 
 
49 
 
 
Primer Name Sequence (5-3) 
  
mCherry 1 FP ACCACCTACAAGGCCAAGAAG 
mCherry 1 RP ACTGTTCCACGATGGTGTAGTC 
mCherry 2 FP ACGGCGAGTTCATCTACAAGG 
mCherry 2 RP AGCCCATGGTCTTCTTCTGC 
SF3A2 FP GCGTTAGAGACCATCGACATCAATAA 
SF3A2 RP AGTGTGTGCAAGATAACTCCCCT 
Table 3: Sequence structures of primer pairs for use in RT-qPCR quantification of nploc4 
 
 
3.6.3c Reverse transcription 
 
Reaction mixture assembled containing 1 µl nploc4 WT/MUT RNA, 2 µl random 
decamers, 2 µl RT buffer, 4 µl dNTP mix, 1 µl RNase inhibitor, 1 µl Reverse 
transcriptase and 9 µl DEPC-H2O. Mixture spun briefly and incubated in 
thermocycler at 44oC for 60 minutes, and 92OC for 10 minutes > Storage prepared 
cDNA. 
 
3.6.3d RT-qPCR 
PCR mixture made up containing (for each reaction): 2 µl cDNA product, 2.5 µl 
10x PCR buffer, 1.25 µl relevant forward primer, 1.25 µl relevant reverse primer, 
1.25 µl dNTP mix, 0.2 µl TAQ polymerase and finally dH2O up to 20 µl. 
Reaction mixtures are assembled in triplicate for each primer pair (mCherry 1, 
mCherry 2 and SF3A2) and run in lidded PCR tube strips with the following PCR 
cycle: 
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PCR Cycle: Temp (°C) Time (s) 
Cycle 1 
 
  
Step 1: 50 120 
Cycle 2 (1x) 
 
  
Step 1 95 600 
Cycle 3 (40x) 
 
  
Step 1 95 15 
Step 2 60 60 
Cycle 4 (81x) 
 
  
Step 1 55-95 30 
Table 4: PCR protocol for RT-qPCR quantification of nploc4 
 
 
Melting curve data was automatically collected and recorded in real-time 
throughout the PCR. 
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RESULTS 
 
4.1 Selection of nploc4 as a novel candidate for experimental 
validation of CAGE predicted miRNA targeting 
 
Using Danio rerio RNA expression libraries created by Yao et al. (2014), and Wei 
et al. (2012) (detailed in methods), ideal candidates for experimental validation of 
CAGE predicted miRNA targeting were selected. Only genes that are expressed 
maternally, possess at least one CAGE predicted maternal miRNA target site and 
show an expression pattern consistent with a gene targeted by maternal miRNA 
are selected. 
 
4.1.1 Identification of maternal miRNAs 
 
RNA expression data was filtered to identify only miRNAs predominantly active 
during pre-MBT stages. This step was performed by academic collaborator and 
computational biologist Chirag Nepal of the University of Copenhagen. Six 
maternal miRNAs were identified as being predominantly active in maternal 
stages; let-7a, miR-1, miR-17a, miR-22a, miR-93 and miR-206 (table 2 & 3, 
below).  
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miRNA 
miRNA expression (RPKM) 
1 cell 16 cell Other late stages 
 dre-let-7a 613 1014 1207 1029 2363 2595 3100 25732 
dre-miR-1 855 268 326 283 1080 674 228134 503222 
dre-miR-206 2772 100 112 126 7605 71080 229877 142202 
dre-miR-17a 27 20 11 17 240 816 2333 924 
dre-miR-93 46 44 7 12 177 600 2070 1246 
dre-miR-22a 2886 3744 1216 1442 2758 6409 20148 33976 
Table 5: Danio rerio expression data by stage for maternally inherited miRNAs derived 
from the library of Yao et al. (2014). 
 
 
miRNA 
miRNA expression (RPKM) 
256 cell Other late stages 
 dre-let-7a 2373 415 835 2852 
dre-miR-1 215 584 620 46776 
dre-miR-206 365 5979 749 120989 
dre-miR-17a 852 659 46 4235 
dre-miR-93 1933 3036 414 38836 
dre-miR-22a 14865 6339 485 25130 
Table 6: Danio rerio expression data by stage for maternally inherited miRNAs derived 
from the library of Wei et al. (2012). 
 
 
4.1.2 Identification of candidate miRNA potential gene targets 
 
Identification of potential gene targets of the six mentioned maternally active 
miRNAs was also performed by Chirag Nepal. The RNA library is filtered to select 
for genes showing an expression pattern consistent with maternal miRNA 
degradation (Figure 17). 
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Figure 17: A graph representing an ideal expression pattern for a candidate maternal 
miRNA target gene (i.e. The SLC41A2 gene, targeted by miR-22). RPKM: Reads per 
kilobase per million ([# of mapped reads]/([length of transcript]/1000)/([total reads]/10^6). 
 
Filtering of the library resulted in a potential 54 target genes that were expressed 
in all three maternal stages (≥5 tpm), and whose expression levels were higher (at 
least ≥1.5 fold in at least two pre-MBT stages) during Pre-MBT stages as 
compared to MBT stages (representing degradation during MBT). These 54 target 
genes were manually viewed (by me) on the UCSC Genome Browser to both 
confirm expression patterns throughout early development, and to identify ideal 
candidates with no or few conflicting CAGE predicted target sites (Figure 18).  
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Figure 18: UCSC Genome Browser image showing nploc4 3’UTR and CAGE predicted 
miRNA target sites during early development. nploc4 is a good candidate with relatively 
few miRNA targets in its 3’UTR at early stages. A: nploc4 3’UTR. B: miRNA CAGE 
predicted target sites. 
 
 
4.1.3 nploc4 as a CAGE predicted miRNA target for experimental 
validation 
 
The nploc4 gene on chromosome 12 of the zebrafish shows both a CAGE 
predicted miR-430 target site (Figure 18, above), and an expression pattern 
consistent with miR-430 degradation (Fig 19, below) and, As such, nploc4 was 
chosen as the most suitable predicted miRNA target for experimental validation as 
a ‘true’ target site, as predicted by CAGE data. 
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Figure 19: Graph representing zebrafish nploc4 expression pattern at early developmental 
stages, derived from UCSC Genome Browser RefSeq data (Nepal et al. 2013).  nploc4 
shows sharp degradation in the MBT transition, followed by a slow rise at later stages, 
consistent with miR-430 degradation. 
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4.2 Experimental validation of the cxcr7b gene as a miR-430 
target via fluorescent imaging assay (proof of concept) 
 
4.2.1 Overall cxcr7b mCherry expression 
 
 
Prior to experimental validation of nploc4 as a true CAGE predicted target site, 
cxcr7b was identified as an ideal previously experimentally validated miR-430 
target to use as a proof of concept test to validate our own experimental method 
for determining a ‘true’ CAGE predicted miRNA target. Zebrafish embryos in 
cxcr7b WT and MUT treatment groups (injected with a functional miR-430 cxcr7b 
seed site and a mismatched non-functional cxcr7b seed site respectively) are 
examined at 72hpf for measurement of both mCherry and CFP fluorescence levels 
via automatic fluorescent microscopy as a measurement of mRNA expression 
(Figure 20). 
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Injection Group n Mean mCherry fluorescence Std Dev 
cxcr7b WT 54 0.17 0.42 
cxcr7b MUT 40 0.38 0.31 
Figure 20: Bar chart and table representing differences and standard deviations in overall 
mCherry fluorescence throughout the whole embryo (sum of each segment average) 
between cxcr7b Wild Type injected (n=54), and cxcr7b mutated (n=40) embryos. mCherry 
expression is normalised against average CFP values. 
 
 
 
Figure 20 represents relative overall mCherry fluorescence (i.e. cxcr7b 
expression) of both cxcr7b wild type injected and cxcr7b mutant injected embryos. 
Overall mCherry expression was calculated via the summation of each separate 
embryo segments (Yolk, Eye, Skin, Brain, Cerebellum, Heart, Notochord and 
Spinal Cord (Figures 27 & 28 in appendices)) relative average mCherry 
expression values as determined via RFP channel fluorescent imaging and zMiner 
quantification of expression (Gehrig et al., 2009). All values are expressed after 
normalisation against individual embryo CFP fluorescence values (RFP/CFP) to 
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account for variations in RNA injection amounts between embryos (CFP linked to 
invariant gene). The relative expression of cxcr7b is significantly increased (p = 
0.007, Mann-Whitney U test) in the mutated embryos (those with mismatches 
induced within cxcr7b 3’UTR seed site to prevent miR-430 mediated suppression 
of translation and mRNA degradation) in comparison to the wild type (functioning 
miR-430 seed site) embryos. 
 
 
4.2.2 Overall cxcr7b CFP expression as a normalisation control 
 
 
As mentioned previously, CFP was used as a fluorescent marker linked to an 
invariant gene (SF3A2) co-injected with cxcr7b and unaffected by maternal mRNA 
degradation. This allowed its use as a normalisation control, to control against 
variations in RNA injection amounts between individual embryos. Representing 
mCherry expression as a ratio against CFP expression allowed for normalisation 
against any differences in amount of RNA injected. A comparison of CFP 
expression values between WT and MUT treatment groups was made, as any 
significant variations between the two groups may confer experimental flaws 
(Figure 21). 
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Injection group n Mean CFP fluorescence Std Dev 
cxcr7b WT 54 45.48 12.49 
cxcr7b MUT 40 47.48 13.44 
Figure 21: Bar chart and table representing differences in overall CFP expression 
values between cxcr7b wild type (n=54) and cxcr7b mutated (n=40) embryos. 
 
 
As seen in Figure 21, CFP expression levels are relatively consistent between 
treatment groups, represented by mean CFP fluorescent levels of 45.48 in the 
cxcr7b wild type embryos and 47.48 in the cxcr7b mutant embryos. These results 
do not significantly differ from each other statistically (p>0.05, Mann-Whitney U 
test), reflecting relatively consistent RNA injections between the two treatment 
groups.  
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4.3 Experimental validation of the nploc4 gene as a miR-430 
target via fluorescent imaging assay and RT-qPCR analysis 
 
4.3.1 Overall mCherry expression determination via fluorescence 
assay 
 
Given the preliminary findings supporting our methodology for determining gene 
expression differences in the cxcr7b trial run, the methodology was repeated, with 
the use of a novel, CAGE predicted miR-430 target - nploc4. The same 
methodology was followed as with previous cxcr7b validation, but with nploc4 WT 
and MUT injections as opposed to cxcr7b. 
A comparison of mCherry fluorescence (normalised against CFP expression) 
between both nploc4 WT and nploc4 MUT injected embryos was made at 72hpf 
(Figure 22) to compare relative nploc4 expression as a measurement of miR-430 
mediated degradation (Figure 23). 
 
 
Figure 22: Olympus Scan^R fluorescent image comparing nploc4 WT (left) and 
MUT (right) embryos, showing mCherry fluorescence at 72hpf. 
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The results obtained in the fluorescence assay of nploc4 as a CAGE predicted 
target of miR-430 are similar to those of the cxcr7b assay. There is a statistically 
significant (p=0.002, Mann-Whitney U test) difference in mCherry fluorescence 
values (and consequently, nploc4 expression) between nploc4 WT and nploc4 
MUT embryos (Figure 23), with statistically significant reduced expression seen in 
the wild type embryos. CFP expression between WT and MUT nploc4 embryos 
does not differ by a statistically significant amount (p>0.05) as seen in Figure 24. 
 
 
 
 
 
Injection Group n Mean mCherry fluorescence Std Dev 
nploc4 WT 36 0.019 0.04 
nploc4 MUT 41 0.091 0.13 
Figure 23: Bar chart and table representing differences and standard deviations in overall 
mCherry fluorescence throughout the whole embryo (sum of each segment average) 
between nploc4 Wild Type injected (n=36), and nploc4 mutant  (n=41) embryos. mCherry 
expression is normalised against average CFP values. 
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Injection Group n Mean CFP fluorescence Std Dev 
nploc4 WT 36 42.58 11.81 
nploc4 MUT 41 47.91 17.59 
Figure 24: Bar chart and table representing differences in overall CFP expression values 
between nploc4 wild type (n=36) and nploc4 (n=41) mutated embryos. 
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4.3.2 Overall nploc4 expression quantification via RT-qPCR 
 
As a follow up to the quantification of relative nploc4 expression between WT and 
MUT treatment groups via fluorescence assay, quantitative reverse transcription 
polymerase chain reaction (RT-qPCR) was subsequently performed as a 
secondary measurement to support the fluorescent assay findings. Two 
(successful) RT-qPCR runs were performed on nploc4 WT and MUT RNA 
samples to determine relative nploc4 expression between the two groups. 
mCherry linked nploc4 expression was normalised against the invariant Beta-actin 
gene (Figures 25 & 26). 
 
 
 
RT-qPCR determined nploc4 mCherry expression
(SFA normalised) [Run 1]
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Figure 25 Bar chart representing mean and SD values for relative mCherry expression in 
both nploc4 wild type (1.02, 0.15) and mutant (2.00, 0.01) embryos as determined by RT-
qPCR (Run 1). mCherry expression values normalised against invariant exogenous gene 
detection (SFA). 
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RT-qPCR determined nploc4 mCherry expression
(SFA normalised) [Run 2]
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Figure 26: Bar chart representing mean and SD values for relative mCherry expression in 
both nploc4 wild type (0.84, 0.00) and mutant (1.11, 0.00) embryos as determined by RT-
qPCR (Run 2). mCherry expression values normalised against invariant exogenous gene 
detection (SFA). 
 
 
 
The two RT-qPCR runs were performed to confirm that no drastic differences are 
seen in the direct measurement of nploc4 expression in an embryonic RNA 
sample and as such, in-depth analysis of the PCR data was not performed 
(including CFP analysis). Figures 25 & 26 however, show results similar to those 
found in the nploc4 fluorescence assay, with increased nploc4 expression seen in 
the MUT group as compared to the WT group seen in both runs (each run consists 
of 15 WT and 15 MUT injected embryos), supporting the fluorescence assay 
findings. 
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Discussion & Conclusions 
 
The main aim of this short laboratory project was to somewhat elucidate the 
potential for CAGE data to be used as a predictor for genuine miRNA target sites 
within the Danio rerio genome – with the possibility that, if successful, CAGE may 
be used in conjunction with current methods to reduce false-positive target site 
identification. Using CAGE data of early stage (72hpf) zebrafish generated by 
Chirag Nepal, we set out to identify a CAGE predicted maternal miRNA target site, 
and to confirm its authenticity as a true target experimentally. In the context of this 
project, our initial findings appear to support the potential for CAGE to do just that. 
nploc4, our identified target site candidate gene showed significantly reduced 
expression (mean fluorescence values of 0.019 WT vs 0.91 MUT (p<0.05 – Figure 
22, and relative expression values of 1.02  WT vs 2.00 - Figure 25, and 0.84 WT 
vs 1.11 MUT – Figure 26 (p<0.05) via RT-qPCR) at 72hpf after injection into 1-cell 
zebrafish embryos when the wild type and intact miR-430 seed site was present, 
in comparison to the relatively increased expression seen in the mutant seed site. 
Coupled to this, expression values of the CFP linked SF3A2 invariant gene did not 
show a significant difference between WT and MUT treatment groups (mean CFP 
fluorescence of 42.58 WT vs 47.91 MUT (p>0.05) – Figure 24), giving some 
confidence in degradation differences being attributable to the seed site 
mismatches between the treatment groups and subsequent variation in miR-430 
degradation, as opposed to being due to uncontrolled exogenous degradation. 
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These findings could suggest that nploc4 was indeed a ‘bona fide’ miR-430 
miRNA target, as predicted by Chirag Nepal’s CAGE data. For this to be true 
however, we need to make a number of assumptions. Firstly, we must assume 
that miR-430 was the sole acting miRNA in causing nploc4 degradation during the 
experiment. The consistent CFP fluorescence in a control supports this, but it is 
still possible that some other confounding miRNA, or a non-specific exogenous 
factor acted to affect the changes seen in the nploc4 expression. This shows one 
problem of this project – testing just one potential miRNA target site (out of the 
thousands of candidates) is a very small first step to testing the usefulness of 
CAGE based miRNA target site prediction, especially considering the pre-existing 
problems with both false-positive and false-negative target site prediction. To 
show the value of CAGE (if any exists) based predictions, hundreds, and ideally 
thousands of novel CAGE identified miRNA target sites would have to be tested 
and experimentally validated as true sites. Only with a large sample size could you 
overcome the inherent chance involved with miRNA target site prediction – one 
result in and of itself could not be used meaningfully. 
 
Further to the small sample size, it appears, in retrospect, that the computational 
data provided by Chirag Nepal as the basis for this project – namely, apparent 
CAGE tag enrichment relating to miRNA seed sites within 3’ UTRs was flawed. 
When running further computational bioanalysis in an attempt to narrow 
parameters for identifying potential miRNA targets, Chirag found confounding 
results. The CAGE data analysis now showed CAGE tag enrichment for genes 
that should not be targeted by any currently identified maternal miRNAs in the 
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maternal stages of embryo development (source data unavailable). If this was not 
an artefact of incorrect analysis of the CAGE data, then it would suggest that the 
CAGE tags are not actually related to miRNA cleavage events or mi-RNA-mRNA 
interactions – considering that the genes showing enrichment shouldn’t be 
undergoing miRNA degradation in the first place. Unfortunately, this contradicting 
data was only uncovered near to the end of the project, and any attempt to 
uncover the cause for such conflicting results was not possible for Chirag at the 
time. To further this, it is unfortunate indeed that near the end of the project the 
very data used in justification for testing CAGE as a predictive tool in miRNA 
targeting was shown to be flawed by Chirag, as this appears to be a novel 
hypothesis based on a finding unique within his own research – and not supported 
by other literature in the field of RNA genomics and computational biology. 
 
In regards to the methodology of this project, previous work using CAGE in the 
mapping of promoter-enhancer interactions in zebrafish embryos (Gehrig et al., 
2009), showed the effectiveness of high throughput automated zebrafish embryo 
imaging via the use of fluorescent microscopy and zMiner software to determine 
overall and segmented gene expression of particular genes of interest. The 
combination of automated embryo detection, automated spatial orientation of the 
embryo, automated 3d imaging of the identified embryo under multiple wavelength 
filters and the use of zMiner software to quantitatively determine and compare 
segmented fluorescence values from those images allowed the high-throughput 
comparison of hundreds of individual embryos in an objective manner. While this 
method does allow high-throughput imaging and fluorescent quantification of gene 
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expression, it does have some downsides. The custom software for detection and 
automated orientation of embryos within 96 well plates does not have much 
margin of error in the original orientation of embryos – it can only compensate for 
deviances from its ‘model’ embryo orientation (Figure 15) to a very small degree – 
which can result in ‘failed detection’ of up to 1/3 of a 96 well plate of embryos in 
some cases, whereby embryos simply are not ‘detected’ by the software. Further, 
in quantifying fluorescence expression within the embryos, and equating this to 
gene expression, relatively large standard deviations were seen, both in the 
cxcr7b and nploc4 fluorescence experiments (i.e. mean fluorescence of  0.019 
and SD of 0.04 in nploc4 WT, and 0.091 mean fluorescence and SD of 0.13 in 
MUT – Figure 23). This suggests large variations in the fluorescent values 
quantified in individual embryos of the same group furing fluorescence assays,  
and may reflect a weakness in the methodology of fluorescence measurement via 
automated imaging. It should be noted that while only a perfunctory RT-qPCR was 
run on the embryos, much smaller SD’s and variation was measured between 
samples (Figure 33, appendices) as compared to measurement of gene 
expression via the fluorescent assay. 
 
In conclusion, it would be fair to say that the biggest benefit of this research 
project was in the practical experience gained in the laboratory setting – the 
introduction to zebrafish and their use in genomics (Schier, 2013, Cifuentes et al., 
2010), and experience in the many procedures outlined in the methods section. In 
terms of advancing CAGE data, and 3’ UTR CAGE tag enrichment as a predictor 
for miRNA target sites, this is hard to justify without concrete and stringent 
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computational analysis of the data to produce clear indications of true miRNA 
activity at a particular site, and importantly, at a particular time. It is only after such 
data can be reliably and consistently produced that it should be pursued as a 
potential predictive tool. 
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APPENDICES 
 
 
 
Graph representing region specific mCherry fluorescence differences 
between CXCR7b WT and  MUT embryos
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Figure 27: Bar chart representing average mCherry fluorescence (CFP 
normalised) values for individual segments within the zebrafish embryo. cxcr7b 
wild type and cxcr7b mutant embryos are compared after imaging at 72hpf. 
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 Region specific mCherry fluorescence differences 
between nploc4 WT and CERB mutated embryos
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Figure 28:  Bar chart representing average mCherry fluorescence (CFP 
normalised) values for individual segments within the zebrafish embryo. nploc4 
wild type and nploc4 mutant embryos are compared after imaging at 72hpf. 
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Figure 29: Side by side 
comparison of multiple 
Cxcr7b WT (left) and 
Cxcr7b MUT (right) 
embryos showing 
mCherry expression 
under an RFP filter at 
72hpf.  
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Figure 30: Side by side 
comparison of multiple 
Cxcr7b WT (left) and 
Cxcr7b MUT (right) 
embryos showing CFP 
expression under a 
CFP filter at 72hpf.  
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Figure 31: Side by side 
comparison of multiple 
Cxcr7b WT embryos 
showing both mCherry 
expression (left) and 
CFP expression (right) 
at 72hpf. 
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Figure 32: Side by side 
comparison of multiple 
Cxcr7b MUT embryos 
showing both mCherry 
expression (left) and 
CFP expression (right) 
at 72hpf. 
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Figure 33:  RT-qPCR standard curve for run 1 of the nploc4 mCherry 
quantification. SYBR green fluor was used. Samples were loaded in triplicates with 
the following primers: mCherry 1, mCherry 2, Beta-actin (relative control) and SFA 
(input control). 
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